Immuneel Therapeutics explores use of AI-driven frameworks for biologics, ADCs, in-vivo gene-based therapies

image credit- freepik

In a major step towards transforming the treatment landscape for high burden diseases such as cancers and autoimmune disorders, Bengaluru-based Immuneel Therapeutics and Manas AI, Inc. (based in the US) are entering into a strategic partnership to evaluate the potential application of artificial intelligence (AI)-native tools within the landscape of biologics, antibody-drug conjugates (ADCs), novel allogeneic and in vivo gene-based therapies.

This collaboration aims to assess how Immuneel may leverage Manas AI’s neuro-symbolic models to facilitate the ability to develop and deliver advanced treatments affordably and at scale rapidly.

The integration of Immuneel’s research & development, translational and GMP-grade biomanufacturing capabilities with Manas AI’s AI-native discovery engine, aims to shorten development timelines and accelerate access to therapies that can change the course of disease and improve quality of life.

The collaboration has the potential to span multi-specific antibody designs, AI-optimized binders, payload/linker discovery for ADCs, manufacturability screening, and next-generation allogeneic and in vivo delivery approaches. These capabilities are critical for creating medicines that are not only scientifically advanced but also safer, more scalable, and financially accessible.

Together, the companies intend to determine if a feedback loop—from AI-driven in silico design to development, preclinical testing and scalable manufacturing—can be effectively established and ultimately enable faster iteration, better predictability, and more audit-ready development pathways.